Edition:
India

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

5,989JPY
14 Jun 2019
Change (% chg)

¥-39 (-0.65%)
Prev Close
¥6,028
Open
¥6,020
Day's High
¥6,039
Day's Low
¥5,964
Volume
1,554,000
Avg. Vol
2,147,466
52-wk High
¥6,209
52-wk Low
¥3,277

Select another date:

Thu, May 23 2019

Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business

TOKYO Japan's Daiichi Sankyo Co Ltd is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

UPDATE 2-Daiichi Sankyo looking to sell OTC drug unit for about $900 mln -Nikkei Business

* Company denies it is negotiating sale of unit (Adds company comment, background)

Daiichi Sankyo looking to sell OTC drug unit for about $900 mln - Nikkei Business

TOKYO, May 23 Japan's Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

UPDATE 1-FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

May 14 Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

FDA advisory panel votes against Daiichi Sankyo's cancer treatment

May 14 Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan's Daiichi Sankyo's met its main goal in a mid-stage study, bolstering their position in a highly competitive oncology market.

MEDIA-India's Ex-Ranbaxy promoters diverted funds, Daiichi Sankyo tells Supreme Court - Times Of India

- Note: Reuters has not verified this story and does not vouch for its accuracy

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

Select another date: